• CAREERS
  • EVENTS
  • LIBRARY
  • NEWS
logo-small
Veristat_logo
  • Why Veristat
    • About Us
    • Our Approach
    • Our Leadership
    • Corporate Responsibility
    • Success Stories
    • News
    • Locations
    • Careers
      • Open Positions
      • Core Values
      • Explore Benefits
      • Grow Your Career
      • Because We Care
      • Why Veristat
  • Therapeutic Areas
    • Oncology/Hematology
    • Neurology/Psychiatry
    • Endocrine/Metabolic
    • Inflammation/Immunology
    • Infectious Disease
      • COVID-19
    • Cardiovascular Disease
    • More Therapy Areas
  • Solutions
    • Biologics
      • Cell and Gene Therapies
      • Vaccine Trials
    • Rare Diseases
      • Pediatric
    • Decentralized Trials
    • Rescue Trials
    • Full Service
      • Clinical Trial Planning
      • Clinical Trial Conduct
      • Regulatory Submission
    • Natural History Trials
  • Services
    • Strategic Consulting
      • Adaptive Designs
      • Statistical Power
    • Regulatory Affairs
      • Regulatory Consulting
      • Marketing Applications
      • Chemistry, Manufacturing, and Controls (CMC)
      • Agency Meetings
      • Regulatory Publishing
      • Medical Devices/IVDs
    • Clinical Operations
      • Project Management
      • Monitoring & Site Management
      • Patient Recruitment
      • Patient Retention & Site Engagement
    • Medical Affairs
      • Clinical Trial Safety
      • Data Monitoring Committees
      • Medical Monitoring
    • Medical Writing
    • Biometrics
      • Data Management
      • Biostatistics
      • Data Monitoring Committees
      • Statistical Programming
      • Standards Implementation
    • Pharmacovigilance
    • Resourcing/FSP
  • Knowledge Base
    • Library
    • Blog
    • Webinars
    • Podcasts
    • Success Stories
    • Newsletter
  • Contact Us
  • RFP
  • Why Veristat
    • About Us
    • Our Approach
    • Our Leadership
    • Corporate Responsibility
    • Success Stories
    • News
    • Locations
    • Careers
      • Open Positions
      • Core Values
      • Explore Benefits
      • Grow Your Career
      • Because We Care
      • Why Veristat
  • Therapeutic Areas
    • Oncology/Hematology
    • Neurology/Psychiatry
    • Endocrine/Metabolic
    • Inflammation/Immunology
    • Infectious Disease
      • COVID-19
    • Cardiovascular Disease
    • More Therapy Areas
  • Solutions
    • Biologics
      • Cell and Gene Therapies
      • Vaccine Trials
    • Rare Diseases
      • Pediatric
    • Decentralized Trials
    • Rescue Trials
    • Full Service
      • Clinical Trial Planning
      • Clinical Trial Conduct
      • Regulatory Submission
    • Natural History Trials
  • Services
    • Strategic Consulting
      • Adaptive Designs
      • Statistical Power
    • Regulatory Affairs
      • Regulatory Consulting
      • Marketing Applications
      • Chemistry, Manufacturing, and Controls (CMC)
      • Agency Meetings
      • Regulatory Publishing
      • Medical Devices/IVDs
    • Clinical Operations
      • Project Management
      • Monitoring & Site Management
      • Patient Recruitment
      • Patient Retention & Site Engagement
    • Medical Affairs
      • Clinical Trial Safety
      • Data Monitoring Committees
      • Medical Monitoring
    • Medical Writing
    • Biometrics
      • Data Management
      • Biostatistics
      • Data Monitoring Committees
      • Statistical Programming
      • Standards Implementation
    • Pharmacovigilance
    • Resourcing/FSP
  • Knowledge Base
    • Library
    • Blog
    • Webinars
    • Podcasts
    • Success Stories
    • Newsletter
  • Contact Us
  • RFP
Home > library Library

Veristat Resource Library

Approvals for an Ultra-Rare Hematologic Malignancy

Regulatory Submission Strategy and Novel Efficacy Endpoint for Treatment of an Ultra-Rare and Aggressive Hematologic Malignancy                                                

A small biotech company engaged Veristat early in clinical development for help with a novel biologic being tested for treatment of an ultra-rare and aggressive hematologic malignancy with no available effective therapies. Using the results of a single-arm Phase I/II study, Veristat and the sponsor company collaborated to present a thorough, well-planned strategy for demonstrating the benefits and risks of the targeted therapy in this patient population to regulatory authorities. Based on Veristat’s significant experience, the sponsor engaged our team for strategic consulting, statistical and programmatic support, and medical writing to plan and execute the marketing application process, eventually leading to both FDA and EMA approval.

download
Explore Our Key Related Services
Why Veristat?
  • About Us
  • Our Approach
  • Our Leadership
  • Success Stories
  • News
  • Locations
  • Careers
Therapeutic Areas
  • Oncology/Hematology
  • Neurology/Psychiatry
  • Endocrine/Metabolic
  • Inflammation/Immunology
  • Infectious Disease
  • Cardiovascular Disease
  • More Therapy Areas
Solutions
  • Biologics
  • Rare Diseases
  • Decentralized Trials
  • Rescue Trials
  • Full Service
  • Natural History Trials
Services
  • Strategic Consulting
  • Regulatory Affairs
  • Clinical Operations
  • Medical Affairs
  • Medical Writing
  • Biometrics
  • Pharmacovigilance
  • Resourcing/FSP
  • Privacy Policy

© 2025 Veristat, LLC. All rights reserved. Veristat is a trademark of Veristat, LLC. All other trademarks are the property of their respective owners.

FacebookTwitterLinkedInYouTube
Return to Top

Please fill out this form to access your resource.

Approvals for an Ultra-Rare Hematologic Malignancy

Acceptance of Privacy Policy

By submitting this form, I agree to receive other communications from Veristat. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.